<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04575857</url>
  </required_header>
  <id_info>
    <org_study_id>STUDY00008837</org_study_id>
    <secondary_id>5R34HL143279</secondary_id>
    <nct_id>NCT04575857</nct_id>
  </id_info>
  <brief_title>Role of Statins In Slowing Rheumatic Heart Disease (RHD) Progression</brief_title>
  <official_title>Role of Statins In Slowing Rheumatic Heart Disease (RHD) Progression: A Feasibility Study For A Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Washington</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Manmohan Cardiothoracic Vascular and Transplant Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Washington</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this study is to address specific implementation questions necessary and&#xD;
      sufficient to ensure the feasibility of the larger randomized trial examining the efficacy of&#xD;
      statin medications in slowing rheumatic heart disease (RHD) valvular pathology progression.&#xD;
      This feasibility study is intended to confirm the number of readily recruitable subjects,&#xD;
      assess recruitment rate, and assess the rate of valve pathology via echocardiograms. These&#xD;
      results are necessary and sufficient to facilitate the successful design of a large full&#xD;
      scale randomized trial to determine whether statins improve outcomes in RHD. Successful&#xD;
      treatment of RHD would fundamentally shift the RHD management paradigm world-wide, improve&#xD;
      the lives of millions afflicted with RHD, and subsequently, decrease health care spending on&#xD;
      RHD management.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 2021</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Enrollment rate</measure>
    <time_frame>Measured at study enrollment</time_frame>
    <description>Defined as the proportion of approached eligible participants who consent to enroll in the study</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Medication adherence</measure>
    <time_frame>Measured at month 1</time_frame>
    <description>The investigators will conduct a pill count to assess medication adherence and will report per participant as the percent of pills taken</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Medication adherence</measure>
    <time_frame>Measured at months 6</time_frame>
    <description>The investigators will conduct a pill count to assess medication adherence and will report per participant as the percent of pills taken</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Medication adherence</measure>
    <time_frame>Measured at months 12</time_frame>
    <description>The investigators will conduct a pill count to assess medication adherence and will report per participant as the percent of pills taken</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Medication adherence</measure>
    <time_frame>Measured at months 18</time_frame>
    <description>The investigators will conduct a pill count to assess medication adherence and will report per participant as the percent of pills taken</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Retention rate</measure>
    <time_frame>Measured at Month 18</time_frame>
    <description>Proportion of enrolled participants who come for followup evaluation and remain in the study until its completion</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of progression of valvular disease</measure>
    <time_frame>Change between baseline and Month 18</time_frame>
    <description>Compare month 18 echocardiogram with baseline echocardiogram</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Rheumatic Heart Disease</condition>
  <condition>Valvular Disease</condition>
  <arm_group>
    <arm_group_label>Statin arm</arm_group_label>
    <description>To receive pill packet with atorvastatin (40mg/day) which will be taken nightly.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo arm</arm_group_label>
    <description>To receive pill packet with placebo which will be taken nightly</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atorvastatin</intervention_name>
    <description>Participants in the intervention arm will receive a pill packet with atorvastatin (40mg) x 18 months.</description>
    <arm_group_label>Statin arm</arm_group_label>
    <other_name>Statin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Participants in the control arm will receive a pill packet with placebo x 18 months.</description>
    <arm_group_label>Placebo arm</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        We have developed a comprehensive electronic database of RHD/RF patients in Nepal which&#xD;
        will serve as the main data collection and participant recruitment mechanism.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  ≥ 18 years&#xD;
&#xD;
          -  History of RHD as evidenced by at least one echocardiographic examination&#xD;
&#xD;
          -  No history of cardiac surgery&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  ≥ 75 or &lt; 18 years old&#xD;
&#xD;
          -  Absence of RHD or RF history&#xD;
&#xD;
          -  Active liver disease&#xD;
&#xD;
          -  Impaired hepatic and renal function, including unexplained elevated levels of alanine&#xD;
             transaminase greater than twice the upper limit of normal&#xD;
&#xD;
          -  History of previous statin intolerance or muscle disorders&#xD;
&#xD;
          -  Current pregnancy (by history or lab assessment of beta hCG) or plans for pregnancy in&#xD;
             the next 18 months). Current lactation / breast feeding.&#xD;
&#xD;
          -  LDL &lt;60&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nona Sotoodehnia, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Washington</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nona Sotoodehnia, MD, MPH</last_name>
    <phone>(206) 287-2777</phone>
    <email>nsotoo@uw.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Caitie Hawley, MSPH</last_name>
    <email>cnhawley@uw.edu</email>
  </overall_contact_backup>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 23, 2020</study_first_submitted>
  <study_first_submitted_qc>September 30, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 5, 2020</study_first_posted>
  <last_update_submitted>October 15, 2021</last_update_submitted>
  <last_update_submitted_qc>October 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Washington</investigator_affiliation>
    <investigator_full_name>Nona Sotoodehnia</investigator_full_name>
    <investigator_title>Co-Director, Cardiovascular Health Research Unit</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rheumatic Heart Disease</mesh_term>
    <mesh_term>Rheumatic Diseases</mesh_term>
    <mesh_term>Heart Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atorvastatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

